These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12435521)

  • 81. Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels.
    Suwelack B; Kobelt V; Hillebrand U; Gerhardt U; Matzkies F; Hohage H
    Transplant Proc; 2002 Aug; 34(5):1808-9. PubMed ID: 12176585
    [No Abstract]   [Full Text] [Related]  

  • 82. Oral ulcerations as a sequela of tacrolimus and mycophenolate mofetil therapy.
    Philipone E; Rockafellow A; Sternberg R; Yoon A; Koslovsky D
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Dec; 118(6):e175-8. PubMed ID: 25457894
    [TBL] [Abstract][Full Text] [Related]  

  • 83. New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus.
    Hunt SA
    Cardiol Rev; 2000; 8(3):180-4. PubMed ID: 11174892
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study.
    Mok CC; To CH; Yu KL; Ho LY
    Lupus; 2013 Oct; 22(11):1135-41. PubMed ID: 23995863
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience.
    Gozdowska J; Urbanowicz AL; Galazka Z; Chmura A; Durlik M
    Transplant Proc; 2011 Oct; 43(8):2946-9. PubMed ID: 21996197
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Pulmonary hemorrhage with capillaritis secondary to mycophenolate mofetil in a heart-transplant patient.
    Gorgan M; Bockorny B; Lawlor M; Volpe J; Fiel-Gan M
    Arch Pathol Lab Med; 2013 Nov; 137(11):1684-7. PubMed ID: 24168511
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Miscellaneous treatments, I: sulfasalazine and pentoxifylline: unapproved uses, dosages, or indications.
    Wolf R; Matz H; Orion E; Tüzün B; Tüzün Y
    Clin Dermatol; 2002; 20(5):531-46. PubMed ID: 12435524
    [No Abstract]   [Full Text] [Related]  

  • 89. Anti-TNF therapies--the hope of tomorrow.
    Wolf R; Matz H; Orion E; Ruocco V
    Clin Dermatol; 2002; 20(5):522-30. PubMed ID: 12435523
    [No Abstract]   [Full Text] [Related]  

  • 90. Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review.
    Nobari NN; Goodarzi A
    Dermatol Ther; 2020 Nov; 33(6):e13867. PubMed ID: 32558193
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Tacrolimus: approved and unapproved dermatologic indications/uses-physician's sequential literature survey: part II.
    Sehgal VN; Srivastava G; Dogra S
    Skinmed; 2008; 7(2):73-7. PubMed ID: 18327003
    [TBL] [Abstract][Full Text] [Related]  

  • 92. British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018.
    Berth-Jones J; Exton LS; Ladoyanni E; Mohd Mustapa MF; Tebbs VM; Yesudian PD; Levell NJ
    Br J Dermatol; 2019 Jun; 180(6):1312-1338. PubMed ID: 30653672
    [No Abstract]   [Full Text] [Related]  

  • 93. Tacrolimus in dermatology-pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I.
    Sehgal VN; Srivastava G; Dogra S
    Skinmed; 2008; 7(1):27-30. PubMed ID: 18174798
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Antifungal agents: unapproved uses, dosages, or indications.
    Sehgal VN; Khandpur S
    Clin Dermatol; 2002; 20(5):481-9. PubMed ID: 12435518
    [No Abstract]   [Full Text] [Related]  

  • 95. Practical Management of Immunosuppressants in Dermatology.
    Leis-Dosil VM; Prats-Caelles I
    Actas Dermosifiliogr (Engl Ed); 2018; 109(1):24-34. PubMed ID: 28964393
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Systemic treatment of adult atopic dermatitis.
    Cookson H; Smith C
    Clin Med (Lond); 2012 Apr; 12(2):172-6. PubMed ID: 22586797
    [No Abstract]   [Full Text] [Related]  

  • 97. [Mycophenolate: 30 years later].
    Musette P
    Ann Dermatol Venereol; 2005 Jan; 132(1):7-8. PubMed ID: 15746598
    [No Abstract]   [Full Text] [Related]  

  • 98. Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy?
    de Jong W; de Man RA; Dalm VASH; Reusken CBEM; Goeijenbier M; van Gorp ECM
    J Travel Med; 2019 Sep; 26(6):. PubMed ID: 30850844
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cryosurgery: unapproved uses, dosages, or indications.
    Dawber R
    Clin Dermatol; 2002; 20(5):563-70. PubMed ID: 12435527
    [No Abstract]   [Full Text] [Related]  

  • 100. Guidance for liver transplant immunosuppression.
    Knechtle SJ
    Am J Transplant; 2011 May; 11(5):886-7. PubMed ID: 21466652
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.